Multiple components of the EIF3 are now known to be dysregulated in multiple cancers (EIF3A in breast, cervical, lung and gastric cancers; EIF3B in breast and gastric cancers; EIF3C in testicular cancers; and EIF3H in prostate cancers) (52). Here, EIF3H is linked to prostate cancer.